Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Treatment of chronic hepatitis B infection.

Omata M.

N Engl J Med. 1998 Jul 9;339(2):114-5. No abstract available.

PMID:
9654543
2.

Emerging therapies of hepatitis B and C.

Chen RY, Desmond PV, Locarnini SA.

J Gastroenterol Hepatol. 2002 Dec;17 Suppl:S471-81. Review. No abstract available.

PMID:
12534781
3.
4.

[Lamivudine treatment for hepatitis B].

Lamivudine Clincal Practice Group.

Zhonghua Gan Zang Bing Za Zhi. 2004 Jul;12(7):425-8. Chinese. No abstract available.

PMID:
15487066
5.

Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B.

Villeneuve JP, Condreay LD, Willems B, Pomier-Layrargues G, Fenyves D, Bilodeau M, Leduc R, Peltekian K, Wong F, Margulies M, Heathcote EJ.

Hepatology. 2000 Jan;31(1):207-10.

PMID:
10613747
6.

Lamivudine for chronic hepatitis B and HIV co-infection.

Carton JA, Maradona JA, Asensi V, Rodríguez M, Martínez A.

AIDS. 1999 May 28;13(8):1002-3. No abstract available.

PMID:
10371189
7.

Chemoprevention of hepatocellular carcinoma in chronic hepatitis B with lamivudine?

Lim LY, Kowdley KV.

Gastroenterology. 2005 Dec;129(6):2120-2; discussion 2122. No abstract available.

PMID:
16344085
8.

Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease.

Yuen MF, Seto WK, Chow DH, Tsui K, Wong DK, Ngai VW, Wong BC, Fung J, Yuen JC, Lai CL.

Antivir Ther. 2007;12(8):1295-303.

PMID:
18240869
9.

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, Wu PC, Dent JC, Barber J, Stephenson SL, Gray DF.

N Engl J Med. 1998 Jul 9;339(2):61-8.

10.
11.

Efficacy and tolerability of long-term therapy using high lamivudine doses for the treatment of chronic hepatitis B.

Da Silva LC, Pinho JR, Sitnik R, Da Fonseca LE, Carrilho FJ.

J Gastroenterol. 2001 Jul;36(7):476-85.

PMID:
11480792
12.

Hepatitis B virus infection--natural history and clinical consequences.

Ganem D, Prince AM.

N Engl J Med. 2004 Mar 11;350(11):1118-29. Review. No abstract available. Erratum in: N Engl J Med. 2004 Sep 16;351(12):351.

PMID:
15014185
13.

Favorable efficacy of long-term lamivudine therapy in patients with chronic hepatitis B: an 8-year follow-up study.

Akuta N, Suzuki F, Suzuki Y, Sezaki H, Hosaka T, Someya T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Kumada H.

J Med Virol. 2005 Apr;75(4):491-8.

PMID:
15714490
15.

Natural infection of HBV DNA YMDD variant strains in a chronic hepatitis B patient before treatment with lamivudine.

Yang DH, Liang WF, Zhao NF, Xie YJ.

Hepatobiliary Pancreat Dis Int. 2002 Nov;1(4):539-40. No abstract available.

16.

Regression of cirrhosis associated with hepatitis B e (HBe) antigen-negative chronic hepatitis B infection with prolonged lamivudine therapy.

Yoshida EM, Ramji A, Chatur N, Davis JE, Owen DA.

Eur J Gastroenterol Hepatol. 2004 Mar;16(3):355-8.

PMID:
15195902
17.

[Evaluation of a quantitative HBV-DNA PCR assay in lamivudine treated hepatitis B-infected patients].

Deal C, Ajana F, Canva V, Mouton Y, Yazdanpanah Y, Wattré P, Bocket L.

Ann Biol Clin (Paris). 2002 Sep-Oct;60(5):581-8. French.

18.

Response to lamivudine treatment in children with chronic hepatitis B virus infection.

Hagmann S, Chung M, Rochford G, Jani M, Trinh-Shevrin C, Sitnitskaya Y, Neumann AU, Pollack H.

Clin Infect Dis. 2003 Dec 1;37(11):1434-40. Epub 2003 Nov 6.

PMID:
14614664
19.

Genetic heterogeneity of the precore and the core promoter region of genotype C hepatitis B virus during lamivudine therapy.

Kuwahara R, Kumashiro R, Murashima S, Ogata K, Tanaka K, Hisamochi A, Hino T, Ide T, Tanaka E, Koga Y, Sata M.

J Med Virol. 2004 Jan;72(1):26-34.

PMID:
14635007
20.

Risk of hepatocellular carcinoma in hepatitis B and prevention through treatment.

Sherman M.

Cleve Clin J Med. 2009 May;76 Suppl 3:S6-9. doi: 10.3949/ccjm.76.s3.02. Review.

PMID:
19465708

Supplemental Content

Support Center